FBR Capital Upgrades AMAG Pharmaceuticals To Outperform

Analysts at FBR Capital upgraded AMAG Pharmaceuticals AMAG from Market Perform to Outperform. The target price for AMAG Pharmaceuticals has been raised from $21 to $36. AMAG Pharmaceuticals shares have surged 36.08% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period. AMAG Pharmaceuticals' shares jumped 28.21% to close at $29.72 on Friday.